Oriol Gasch

Dr. Oriol Gasch

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
SPSalvador Pérez-Galera
Salvador Pérez-Galera
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
ECEsther Calbo
Esther Calbo
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro , appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.)

21 July 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ARA. del Rio
A. del Rio
OGOriol Gasch
Oriol Gasch
AMA. Moreno
A. Moreno
CPC. Pena
C. Pena
JCJ. Cuquet
J. Cuquet
FIFOSIMI Investigators
FOSIMI Investigators
Background. There is an urgent need for alternative rescue therapies in invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We assessed the clinical efficacy and safety of the combination of fosfomycin and imipenem as rescue therapy for MRSA infective endocarditis and complicated bacteremia. Methods. The trial was conducted between 2001 and 2010 in 3 Spanish hospitals. Adult patients with complicated MRSA bacteremia or endocarditis requiring rescue therapy were eligible for the study. Treatment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours IV) was started and monitored. The primary efficacy endpoints were percentage of sterile blood cultures at 72 hours and clinical success rate assessed at the test-of-cure visit (45 days after the end of therapy). Results. The combination was administered in 12 patients with endocarditis, 2 with vascular graft infection, and 2 with complicated bacteremia. Therapy had previously failed with vancomycin in 9 patients, daptomycin in 2, and sequential antibiotics in 5. Blood cultures were negative 72 hours after the first dose of the combination in all cases. The success rate was 69%, and only 1 of 5 deaths was related to the MRSA infection. Although the combination was safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload. There were no episodes of breakthrough bacteremia or relapse. Conclusions. Fosfomycin plus imipenem was an effective and safe combination when used as rescue therapy for complicated MRSA bloodstream infections and deserves further clinical evaluation as initial therapy in these infections.

1 November 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
MPMiquel Pujol
Miquel Pujol

12 May 2022 in Eurosurveillance
Verified
Journal Article
Open access
LBLaia Badia-Cebada
Laia Badia-Cebada
JPJudit Peñafiel
Judit Peñafiel
PSPatrick Saliba
Patrick Saliba
MAMarta Andrés
Marta Andrés
JCJordi Càmara
Jordi Càmara
OPOn Behalf Of The Vincat Programme (Infection Control Catalan Programme)
On Behalf Of The Vincat Programme (Infection Control Catalan Programme)
Background: Catheter-related bloodstream infections (CRBSI) are frequent healthcare-associated infections and an important cause of death. Aim: To analyse changes in CRBSI epidemiology observed by the Infection Control Catalan Programme (VINCat). Methods: A cohort study including all hospital-acquired CRBSI episodes diagnosed at 55 hospitals (2007–2019) in Catalonia, Spain, was prospectively conducted. CRBSI incidence rates were adjusted per 1,000 patient days. To assess the CRBSI rate trend per year, negative binomial models were used, with the number of events as the dependent variable, and the year as the main independent variable. From each model, the annual rate of CRBSI diagnosed per 1,000 patient days and the incidence rate ratio (IRR) with its 95% confidence intervals (CI) were reported. Results: During the study, 9,290 CRBSI episodes were diagnosed (mean annual incidence rate: 0.20 episodes/1,000 patient days). Patients’ median age was 64.1 years; 36.6% (3,403/9,290) were female. In total, 73.7% (n = 6,845) of CRBSI occurred in non-intensive care unit (ICU) wards, 62.7% (n = 5,822) were related to central venous catheter (CVC), 24.1% (n = 2,236) to peripheral venous catheters (PVC) and 13.3% (n = 1,232) to peripherally-inserted central venous catheters (PICVC). Incidence rate fell over the study period (IRR: 0.94; 95%CI: 0.93–0.96), especially in the ICU (IRR: 0.88; 95%CI: 0.87–0.89). As a whole, while episodes of CVC CRBSI fell significantly (IRR: 0.88; 95%CI: 0.87–0.91), peripherally-inserted catheter CRBSI (PVC and PICVC) rose, especially in medical wards (IRR PICVC: 1.08; 95%CI: 1.05–1.11; IRR PVC: 1.03; 95% 1.00-1.05). Conclusions: Over the study, CRBSIs associated with CVC and diagnosed in ICUs decreased while episodes in conventional wards involving peripherally-inserted catheters increased. Hospitals should implement preventive measures in conventional wards.

9 October 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
NLNieves Larrosa
Nieves Larrosa

12 February 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
OGon behalf of the REIPI/GEIH Study Groups
on behalf of the REIPI/GEIH Study Groups
A high proportion of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia die within a few days of the onset of infection. However, predictive factors for early mortality (EM) have barely been examined. The aim of this study was to determine the predictive factors for EM in patients with MRSA bacteraemia. All episodes of MRSA bacteraemia were prospectively followed in 21 Spanish hospitals from June 2008 to December 2009. Epidemiology, clinical data, therapy and outcome were recorded. All MRSA strains were analysed in a central laboratory. Mortality was defined as death from any cause occurring in the 30 days after the onset of MRSA bacteraemia. EM was defined as patients who died within the first 2 days, and late mortality (LM) for patients who died after this period. Multivariate analyses were performed by using logistic regression models. A total of 579 episodes were recorded. Mortality was observed in 179 patients (31%): it was early in 49 (8.5%) patients and late in 130 (22.5%). Independent risk factors for EM were [OR (95% CI)] initial Pitt score >3 [3.99 (1.72–3.24)], previous rapid fatal disease [3.67 (1.32–10.24)], source of infection lower respiratory tract or unknown [3.76 (1.31–10.83) and 2.83 (1.11–7.21)], non-nosocomial acquisition [2.59 (1.16–5.77)] and inappropriate initial antibiotic therapy [3.59 (1.63–7.89)]. When predictive factors for EM and LM were compared, inappropriate initial antibiotic therapy was the only distinctive predictor of EM, while endocarditis and lower respiratory tract sources both predicted LM. In our large cohort of patients several factors were related to EM, but the only distinctive predictor of EM was inappropriate initial antibiotic therapy.